14 - 15 May, 2019 | Hotel Novotel Amsterdam Schiphol Airport, Amsterdam, Netherlands

Biosimilars Blog

By: Duncan Emerton PhD - Independent Biosimilars Consultant Chester Pharma Ltd
05/03/2019

What next for biosimilars? Five key questions…

The week, Duncan answers 5 key questions on the biosimilars market and what that holds for the future of biosimilars 

By: Duncan Emerton PhD - Independent Biosimilars Consultant Chester Pharma Ltd
04/17/2019

Keep the faith, the most amazing things in life tend to happen right at the moment you’re about to give up hope…

Here I analyse and critique recent comments from Peter Bach and Mark Trusheim (MIT Sloan) on the U.S Biosimilar Market  

By: Duncan Emerton PhD - Independent Biosimilars Consultant Chester Pharma Ltd
04/04/2019

The role of biosimilars in supporting the sustainable delivery of healthcare today and in the future

"Biosimilars are must-have weaponry in financially sustaining healthcare systems on a global scale as well as significantly improving outcomes for an increasing number of patients throughout Europe and the rest of the world.”

By: Duncan Emerton PhD - Independent Biosimilars Consultant Chester Pharma Ltd
03/25/2019

Is Clinical Differentiation Possible in the Biosimilars Market?

By: Duncan Emerton PhD
03/07/2019

Key recent events from the European and US biosimilars market

This blog will cover key recent events from the European and US biosimilars market, including: insulin generics in the US, pegfilgrastim biosimilar launches in the UK and Canada, and a new dosage form for a trastuzumab biosimilar in Europe

By: Duncan Emerton PhD - Independent Biosimilars Consultant Chester Pharma Ltd
02/20/2019

Will teenage years see the biosimilars market reach new heights, or will its growing pains continue?

Within this Biosimilars market anaysis we review the adoption of Biosimilars across the globe